荚膜型与不可分型流感嗜血杆菌所致侵袭性疾病的继发病例——美国10个辖区,2011-2018年
该研究回顾了美国10个辖区2011-2018年流感嗜血杆菌侵袭性疾病监测数据,评估继发传播。荚膜型Hi疾病患者中继发传播估计患病率为0.32%(间隔≤60天),NTHi疾病患者中为0.12%(间隔≤14天)。所有病例对分离株遗传学高度相关,且所有潜在继发感染患者均有基础疾病。结果强烈提示非b型Hi继发传播存在,扩大化学预防建议或有必要,但需进一步分析获益与风险。
要点
- 荚膜型Hi疾病患者继发传播估计患病率为0.32%(≤60天),NTHi为0.12%(≤14天)。
- 所有Hi病例对分离株遗传学高度相关,潜在继发感染患者均有基础疾病。
- 结果强烈提示非b型Hi继发传播存在,扩大化学预防建议或有必要但需进一步分析。
核心结论
- 结果强烈提示非b型Hi继发传播存在。
- 扩大Hi化学预防建议或有必要以控制美国特定人群侵袭性Hi疾病,但需进一步分析评估潜在获益与风险(如抗生素使用增加)。
研究设计与样本
- 回顾美国10个辖区2011-2018年侵袭性流感嗜血杆菌疾病监测数据,调查继发病例。
- 继发传播估计患病率定义:荚膜型Hi疾病患者间隔≤60天,NTHi疾病患者间隔≤14天。
主要发现
- 荚膜型Hi疾病患者中继发传播估计患病率为0.32%(≤60天)。
- NTHi疾病患者中继发传播估计患病率为0.12%(≤14天)。
- 所有Hi病例对分离株遗传学高度相关。
- 所有潜在继发感染患者均有基础疾病。
关键数值与推荐
- 荚膜型Hi继发传播估计患病率0.32%(≤60天)。
- NTHi继发传播估计患病率0.12%(≤14天)。
- 美国CDC目前不推荐对非b型Hi(包括NTHi)侵袭性疾病患者的接触者进行化学预防。
- ACIP推荐在某些情况下使用抗生素化学预防以预防Hib疾病。
临床怎么用
- 美国CDC目前不推荐对非b型Hi(包括NTHi)侵袭性疾病患者的接触者进行化学预防。
- ACIP推荐在某些情况下使用抗生素化学预防以预防Hib疾病。
- 作者认为扩大Hi化学预防建议或有必要以控制美国特定人群侵袭性Hi疾病,但需进一步分析评估潜在获益与风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Haemophilus influenzae (Hi) can cause meningitis and other serious invasive disease. Encapsulated Hi is classified into six serotypes (a-f) based on chemical composition of the polysaccharide capsule; unencapsulated strains are termed nontypeable Hi (NTHi). Hi serotype b (Hib) was the most common cause of bacterial meningitis in children in the pre-Hib vaccine era, and secondary transmission of Hi among children (e.g., to household contacts and in child care facilities) (1,2) led to the Advisory Committee on Immunization Practices (ACIP) recommendation for antibiotic chemoprophylaxis to prevent Hib disease in certain circumstances.* High Hib vaccination coverage since the 1990s has substantially reduced Hib disease, and other serotypes now account for most Hi-associated invasive disease in the United States (3). Nevertheless, CDC does not currently recommend chemoprophylaxis for contacts of persons with invasive disease caused by serotypes other than Hib and by NTHi (non-b Hi). Given this changing epidemiology, U.S. surveillance data were reviewed to investigate secondary cases of invasive disease caused by Hi. The estimated prevalence of secondary transmission was 0.32% among persons with encapsulated Hi disease (≤60 days of one another) and 0.12% among persons with NTHi disease (≤14 days of one another). Isolates from all Hi case pairs were genetically closely related, and all patients with potential secondary infection had underlying medical conditions. These results strongly suggest that secondary transmission of non-b Hi occurs. Expansion of Hi chemoprophylaxis recommendations might be warranted to control invasive Hi disease in certain populations in the United States, but further analysis is needed to evaluate the potential benefits against the risks, such as increased antibiotic use.
引用
- Oliver SE, Rubis AB, Soeters HM, et al. Secondary Cases of Invasive Disease Caused by Encapsulated and Nontypeable Haemophilus influenzae - 10 U.S. Jurisdictions, 2011-2018. MMWR Morb Mortal Wkly Rep. 2023. PMID: 37053119. doi:10.15585/mmwr.mm7215a2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。